Histrelin
As of the edition of 20 October 2026, Histrelin is a protein: marketed, first approved in 1991 (US); acts on GNRHR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1991
- Kind
- Protein
- Brand name
- Supprelin
- First approved
- 24 December 1991 (US)
- Approvals on record
- 5 in 1 region
- Holder of the most recent approval
- Endo; 2 holders in all
- Registered trials
- 8, 1 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Hormones; Mental health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | P30968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 3 | 7 | 3 | 4 | 0 |
| All trials | 8 |